DisclosureWe earn commission on partner links; ranking is set by our evidence-based methodology — not advertisers. Read policy
In-depth, evidence-graded guides across our full A–Z of 25 health conditions — symptoms, what the research shows, and the treatment options we rank.
PCOS is the most-asked off-label GLP-1 indication. Weight loss, insulin sensitivity, and androgen levels often improve, but FDA approval is not on-label.
MASLD/MASH is the next major GLP-1 expansion. Semaglutide showed Phase 3 efficacy in resolving steatohepatitis without worsening fibrosis. FDA approval expected 2026-2027.
No GLP-1 is FDA-approved for prediabetes, but trials show 60-70% reduction in T2D progression at 3 years. The case for early intervention is strong.
Menopause-driven weight gain responds to GLP-1s similarly to other adult obesity. No menopause-specific indication exists, but real-world data show comparable efficacy.